EDUCATIONAL CONTENT | WORK SAMPLE

Omega-3s Explained: Mechanisms, Absorption, Evidence

Deborah M. Burke-Allen, RPh
Registered Pharmacist
deborahburkeallen.github.io

The short version: EPA and DHA work by becoming part of our cells. They change how cells signal, especially in inflammation, and they build the brain and retina. How well they work depends on the form, the meal they are taken with, and time, because cell membranes change over months, not days.

How They Work: Four Mechanisms

1. They rebuild cell membranes. EPA and DHA are taken up into the phospholipids of cell membranes, changing how those membranes behave and signal [1].

2. They shift inflammatory signals. They partly replace arachidonic acid, the omega-6 fat that makes more potent inflammatory prostaglandins and leukotrienes, and EPA makes milder versions of its own [1].

3. They help inflammation resolve. EPA and DHA are the raw material for resolvins, protectins, and maresins, signals that help switch inflammation off once its job is done [1].

4. They build the brain and eyes. The brain is nearly 60% fat, and DHA is a key structural fat in the brain and the retina, which is why it matters so much in pregnancy and early childhood [2, 3].

Pharmacokinetics: From Softgel to Cell

1. Swallowed with a meal
Dietary fat triggers bile and pancreatic lipase, the enzymes that free the fatty acids.

>

2. Digested
Triglyceride forms are absorbed more readily than ethyl-ester forms, which depend heavily on fat in the meal [4, 5].

>

3. Absorbed
Gut cells repackage the fatty acids into chylomicrons, which enter the lymph and then the blood.

>

4. Built into cells
Red blood cell omega-3 levels rise with dose over about five months, measured as the Omega-3 Index [6, 7].

What this means in practice: take fish oil with a meal that contains fat; choose a triglyceride form when possible; dose by EPA and DHA, not total fish oil; and expect effects to build over weeks to months. In one dose-response trial, the dose of EPA and DHA alone explained about two-thirds of how much a person's Omega-3 Index rose [7].

What the Trials Actually Show

QUESTION	GRADE	WHAT THE EVIDENCE SHOWS
High triglycerides	STRONG	Prescription doses of 4 g a day lower high triglycerides, and the American Heart Association supports their use for this purpose [8]. This is drug territory, not a supplement claim.
Heart events, high-risk patients	MIXED	Purified EPA at 4 g a day cut major cardiovascular events by about 25% in patients with high triglycerides (17.2% vs 22.0%) [9], but a mixed EPA and DHA product showed no benefit against a corn oil comparator [10]. The form and the comparator matter.
Heart events, general population	NEUTRAL	At 1 g a day in nearly 26,000 healthy adults, major cardiovascular events were not significantly reduced over five years [11].
Pregnancy	STRONG	Across 70 trials, omega-3s during pregnancy reduced preterm birth before 37 weeks (13.4% to 11.9%) and early preterm birth before 34 weeks (4.6% to 2.7%), rated high-quality evidence [12].
Attention in youth with ADHD	MODEST	Across seven trials, supplementation modestly improved symptom scores, and these youth had lower EPA and DHA levels [13]. A disease population, so practitioner education only.
Safety	KNOW THIS	No overall increase in bleeding across trials of more than 120,000 patients [14], but doses above 1 g a day were linked to higher atrial fibrillation risk [15].

Red Flags in Supplement Language

Deborah M. Burke-Allen, RPh
Registered Pharmacist
deborahburkeallen.github.io

These phrases appear on omega-3 and other supplement materials constantly. Each one signals a claim that outruns the evidence or the law, and each has an accurate alternative.

> **A teaching point worth repeating:** "omega-3s reduce heart events" is not one claim. One purified EPA drug at 4 g a day in high-risk patients reduced events; a 1 g supplement in healthy adults did not. Good education names the dose, the form, and the population every time.

RED FLAG	WHY IT IS A PROBLEM	SAY THIS INSTEAD
"Treats," "cures," "prevents," or a named disease (eczema, ADHD, heart disease)	A disease claim. Under DSHEA, supplements may describe effects on normal structure or function only.	"Supports brain health."* "Supports heart health."*
"Clinically proven"	Usually borrows ingredient studies done at another dose, form, or population, or with a prescription product.	Name the study: "In a 12-week trial of X adults at Y mg..."
"1,000 mg fish oil"	Total oil, not active omega-3. EPA and DHA may be a third of that, and labels are not always accurate [16].	"Provides X mg EPA and Y mg DHA per serving."
"Pharmaceutical grade"	No regulatory definition for supplements; it implies drug-level standards without proof.	"Third-party tested for purity, potency, and freshness."
"Reduces heart attacks" (from a drug trial)	Applies a 4 g prescription EPA result to a 1 g supplement in healthy people [9, 11].	"Supports heart health as part of a healthy diet."*
"Boosts immunity," "detoxifies," "anti-inflammatory"	Vague or drug-like; implies treating a condition.	"Supports a healthy inflammatory response."*
"No side effects," "safe for everyone"	Untrue: fishy aftertaste, GI upset, and dose-related atrial fibrillation risk [15].	"Ask your practitioner if you take a blood thinner."
"Superior absorption" with no comparison	Superior to what? Unsupported comparisons invite challenge.	"Triglyceride form, absorbed better than ethyl-ester concentrates" [4].
Lab or animal results stated as human benefits	Mechanism is not outcome; cell studies show plausibility, not effect in people.	"Early research suggests..." with the study type named.

Four Questions Before Trusting Any Claim

Dose
Was it studied at the amount in the product?

Form
Same form: triglyceride, ethyl ester, or prescription EPA?

Population
Healthy adults, or a disease group?

Outcome
A real health outcome, or only a lab marker?

Sources (each verified in PubMed): [1] Calder PC. Biochem Soc Trans. 2017;45(5):1105-15. PMID 28900017. [2] Chang CY, et al. Acta Neurol Taiwan. 2009;18(4):231-41. PMID 20329590. [3] SanGiovanni JP, Chew EY. Prog Retin Eye Res. 2005;24(1):87-138. PMID 15555528. [4] Dyerberg J, et al. Prostaglandins Leukot Essent Fatty Acids. 2010;83(3):137-41. PMID 20638827. [5] Lawson LD, Hughes BG. Biochem Biophys Res Commun. 1988;156(2):960-3. PMID 2847723. [6] Harris WS, von Schacky C. Prev Med. 2004;39(1):212-20. PMID 15208005. [7] Flock MR, et al. J Am Heart Assoc. 2013;2(6):e000513. PMID 24252845. [8] Skulas-Ray AC, et al. Circulation. 2019;140(12):e673-91. PMID 31422671. [9] Bhatt DL, et al. N Engl J Med. 2019;380(1):11-22. PMID 30415628. [10] Nicholls SJ, et al. JAMA. 2020;324(22):2268-80. PMID 33190147. [11] Manson JE, et al. N Engl J Med. 2019;380(1):23-32. PMID 30415637. [12] Middleton P, et al. Cochrane Database Syst Rev. 2018;11:CD003402. PMID 30480773. [13] Chang JP, et al. Neuropsychopharmacology. 2018;43(3):534-45. PMID 28741625. [14] Javaid M, et al. J Am Heart Assoc. 2024;13(10):e032390. PMID 38742535. [15] Gencer B, et al. Circulation. 2021;144(25):1981-90. PMID 34612056. [16] Albert BB, et al. Sci Rep. 2015;5:7928. PMID 25604397.